Case Report: Chronic Cavitatory Pulmonary Aspergillosis after COVID-19

Chaurasia, Sheetal; Thimmappa, Manjunath; Chowdhury, Saurav

doi:10.4269/ajtmh.21-0701

Cited by 8 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on this definition, our cases were not classified as CAPA. A case of chronic cavitary pulmonary aspergillosis (CCPA) after COVID-19 has been reported, but this case was quite different from ours because in this case latent aspergilloma was considered to be activated after SARS-CoV-2 infection [ 4 ]. CCPA is characterized by symptoms lasting for at least three months [ 5 , 6 ], and our cases did not meet this criterion even at the time of transfer to the long-term care hospital.…”

Section: Discussionmentioning

confidence: 99%

Chronic Pulmonary Aspergillosis During Convalescence From Severe COVID-19 Treated With Oral Itraconazole: A Report of Two Cases

Horiuchi¹,

Utada²,

Shinomiya³

et al. 2022

Cureus

View full text Add to dashboard Cite

Invasive pulmonary aspergillosis (IPA) has been reported to occur secondary to coronavirus disease 2019 (COVID-19), and the condition has been termed COVID-19-associated pulmonary aspergillosis (CAPA). We diagnosed two severe COVID-19 cases with multiple cavitary lung lesions and chronic pulmonary aspergillosis (CPA) on days 58 and 48 of admission, respectively, with gradual improvement in the respiratory status. Both patients were positive for Aspergillus-precipitating antibodies (APAb). We chose oral itraconazole (ITCZ) for both patients because of its convenience in terms of long-term treatment. Cavitary lesions diminished after ITCZ administration. The risk factors for pulmonary aspergillosis in both patients were determined to be steroid pulse therapy, use of baricitinib, diabetes mellitus (DM), ICU admission, long hospital stay, and the use of broad-spectrum antibiotics. Pulmonary aspergillosis must be suspected in patients with severe COVID-19, even if they are asymptomatic, because not only IPA but also CPA can occur following COVID-19. Therefore, oral ITCZ may be a treatment option for CPA following COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Chronic Pulmonary Aspergillosis During Convalescence From Severe COVID-19 Treated With Oral Itraconazole: A Report of Two Cases

Horiuchi¹,

Utada²,

Shinomiya³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Chaurasia et al [25] reported a rare occurrence of chronic cavitary pulmonary aspergillosis in a COVID-19 patient, a 57-year-old man. Chronic cavitary is usually linked to slightly weakened immune systems or damage to the lungs, and it is not often found in COVID-19 patients.…”

Section: Discussion and A Brief Review Of The Literaturementioning

confidence: 99%

Pulmonary Cavitation as a Complication of COVID-19: Case Series and a Brief Review of the Literature

Aghamohammadi,

Ghodrati,

Etemadi Sh

et al. 2024

AMH

View full text Add to dashboard Cite

The COVID-19 pandemic has led to an unprecedented surge in respiratory illness cases worldwide. Although uncommon, pulmonary cavitation has been reported as a potential complication of COVID-19. This case series report describes four cases of COVID-19 patients with lung cavities, highlighting the various causes and clinical manifestations of this complication, and a review of the literature on the presence of lung cavities in COVID-19 patients. In two cases, the cavities were most likely due to secondary bacterial superinfections, with one case being complicated by multi-drug-resistant bacteria. Another case developed cavities secondary to a fungal infection, while the third case was directly caused by SARS-CoV-2 invasion in the lungs. The presence of cavities with or without air-fluid level or pneumothorax in COVID-19 patients should be considered as a potential complication of this infection, especially in those with respiratory symptoms. Physicians should remain vigilant for the development of pulmonary cavitation in COVID-19 patients, particularly those receiving high doses of steroids. Additionally, spontaneous pneumothorax should be considered an alarming sign in COVID-19 patients.

show abstract

“…Методы ди агностики аспергилломы: характерные рентгенологиче ские симптомы («серпа», «погремушки»); микроскопия и бактериологическое исследование мокроты, бронхо альвеолярной лаважной жидкости; определение спец ифических IgG к грибам рода Aspergillus в сыворотке крови [12]. В 2021 и 2022 г. появились публикации, по священные описанию клинических случаев развития ас пергилломы у пациентов с тяжелым течением COVID19, не имевших ранее полостных образований в легких [13,14]. В одном сообщении аспергиллома у пациентки была расценена как ожидаемое долгосрочное осложне ние после COVID19 с нарушением легочной структуры вследствие баротравмы в результате инвазивной искус ственной вентиляции легких [15].…”

Section: Discussionunclassified

Pulmonary aspergilloma after previous COVID-19: a case report and a literature review

Ovsyannikov,

Bilevich,

Berezhnoy

et al. 2023

CMAC

View full text Add to dashboard Cite

Pulmonary aspergillosis has always been considered as a disease that occurs in patients with certain risk factors for its development. The COVID-19 pandemic has shown that fungal complications are common in patients without aspergillosis risk factors. Thus, invasive aspergillosis is a common complication of COVID-19. There are rare reports of aspergilloma that developed after a severe coronavirus infection in individuals who did not previously have cavitary lesions in the lungs. Development of aspergilloma as an expected long-term complication after COVID-19 may be due to damage of lung structure caused by coronavirus infection, oxygen therapy and mechanical ventilation. This article describes a case report of aspergilloma in a patient with confirmed severe COVID-19 and background chronic diseases without risk factors for fungal infection. A review of publications on the development of aspergilloma in patients following COVID-19 is also presented.

show abstract

Case Report: Chronic Cavitatory Pulmonary Aspergillosis after COVID-19

Cited by 8 publications

References 9 publications

Chronic Pulmonary Aspergillosis During Convalescence From Severe COVID-19 Treated With Oral Itraconazole: A Report of Two Cases

Chronic Pulmonary Aspergillosis During Convalescence From Severe COVID-19 Treated With Oral Itraconazole: A Report of Two Cases

Pulmonary Cavitation as a Complication of COVID-19: Case Series and a Brief Review of the Literature

Pulmonary aspergilloma after previous COVID-19: a case report and a literature review

Contact Info

Product

Resources

About